AstraZeneca, Daiichi Sankyo EU Application Validated for Breast Cancer Treatment

MT Newswires Live02-19

AstraZeneca (AZN) and Daiichi Sankyo had its European Medicines Agency marketing application validated for their targeted therapy Enhertu to treat a specific type of early-stage breast cancer, Daiichi Sankyo said Thursday.

The regulatory approval initiates the formal scientific review process for the medication's use as a standalone option in patients who still have breast cancer following prior treatments, the company said.

The submission relies on late-stage clinical trial data from the Destiny trial showing the drug reduced the likelihood of disease return or mortality by 53% compared to an older treatment, Daiichi Sankyo said.

The drugmakers are also pursuing additional European regulatory approvals for the medication to address other forms of advanced breast cancer and solid tumors, the company added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment